The Liver Meeting 2026
Keynote State of the Art track
Hyman J. Zimmerman Hepatotoxicity State of the Art: Hepatotoxicity Arising From Gene Therapy
Sat, Nov 7, 2026 · 8:00–8:30 AM MST Convention Center: General Session, Hall A, Colorado Convention Center
About this session
Gene therapy encompasses a range of therapeutic strategies that modify or regulate genetic material (DNA or RNA) to treat or prevent disease. Despite substantial clinical advances and multiple U.S. Food and Drug Administration (FDA) approvals, hepatotoxicity has emerged as a significant toxicity across several gene therapy platforms.
Speakers
Reviews of this session
No reviews yet
Were you in the room? Reviews are open until Nov 9, 2027.